A Phase II trial of Dose adjusted EPOCH and Rituximab therapy for newly-diagnosed DLBCL with C-MYC rearrangement
Phase 2
- Conditions
- C-MYC positive diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000015972
- Lead Sponsor
- Kanagawa Clinical Oncology study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
(1) History of glaucoma (2) Uncontrollable diabetes mellitus (3) Uncontrollable hypertension (4) Coronary artery disease under treatment; cardiomyopathy, heart failure, or arrhythmia treated with anti-arrhythmic (5) HBs antigen positive (6) HCV antibody positive (7) HIV antibody positive (8) Interstitial pneumonia, pulmonary fibrosis (9) Severe infection (10) Liver cirrhosis (11) Other active malignancies; history of lymphoma, myelodysplastic syndrome, or leukemia (12) Pregnant, possible pregnant, or breastfeeding woman (13) Severe psychosis (14) Under systemic corticosteroid therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year progression-free survival rate
- Secondary Outcome Measures
Name Time Method Overall response rate, Complete response rate, Overall survival, Toxicity